BioGenes announces management buy-out

The MBO will support future growth by driving innovations for customers and building new strategic partnerships to further expand market position as a leader in host cell assay development.

Dr Alexander Knoll, Managing Director of BioGenes said: "We are delighted to have reached an agreement with the previous shareholders and we would like to take the opportunity to thank them for their loyalty. With their support, BioGenes has been growing strongly over the last years. The MBO will support our future growth strategy by driving innovations for customers and building new strategic partnerships with the aim to further expand our market position as a leader in host cell assay development."

Dagmar Schwertner, Marketing Director of BioGenes said: “BioGenes is known as a trusted and experienced expert in immunoassay, 2D electrophoresis and antibody development and we intend to continue systematically down the path we have started on. High quality standards throughout the whole value chain will of course be ensured in the years ahead.”